Momotaro-Gene Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Momotaro-Gene Inc. - overview
Established
2007
Location
Okayama-shi, Okayama, Japan
Primary Industry
Biotechnology
About
Based in Okayama-shi, Japan, Momotaro-Gene Inc. is engaged in developing innovative cancer therapies that utilize genetic and pharmaceutical combinations to target various tumors effectively. Momotaro-Gene Inc. focuses on creating advanced cancer treatment solutions.
Founded in 2007, the company has undergone strategic developments, raising JPY 499. 920 mn during its SERIES D funding round in April 2023, with investor Adreic Therapeutics Inc. Momotaro-Gene has successfully managed 3 deals to date and boasts a current valuation of JPY 2,415. 529 mn.
Momotaro-Gene Inc. specializes in developing innovative cancer therapies that leverage genetic and pharmaceutical combinations to target various tumors. Their primary offerings include a patented combination therapy utilizing the REIC/Dkk-3 gene and checkpoint inhibitors, aimed at enhancing the effectiveness of existing cancer treatments. Additionally, the company is advancing a method for treating liver cancer that combines REIC/Dkk-3 with antitumor agents.
These therapies are undergoing clinical trials, including phase I/IIa studies conducted at Okayama University Hospital, specifically targeting malignant gliomas. Momotaro-Gene's products are primarily intended for use in the Japanese healthcare market, with potential implications for broader international markets as the development progresses. Momotaro-Gene Inc. generates revenue through strategic partnerships and collaborations within the pharmaceutical industry, particularly focusing on the oncology sector.
The company's business model involves agreements with healthcare institutions and pharmaceutical companies for the co-development and commercialization of their therapeutic solutions. Transactions occur through licensing arrangements, where clinical trial results may lead to further investment and support from partners. Revenue is derived from milestones achieved during the drug development process and potential royalties on future sales of successfully marketed therapies. Details regarding specific pricing structures or revenue figures have not been disclosed.
In April 2023, Momotaro-Gene Inc. raised JPY 500 million in SERIES D funding, which will enable the company to strengthen its financial base. The firm is focused on advancing its innovative cancer therapies, with plans to expand its reach into new geographical markets beyond Japan as development progresses. The funding is expected to support these initiatives, allowing for enhanced research and potential product launches in the coming years.
Current Investors
KYORIN Pharmaceutical , SMBC Venture Capital, Nissay Capital
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Oncology/Cancer Treatment, Pharmaceutical Research & Development
Website
www.mt-gene.com
Company Stage
Series D
Total Amount Raised
Subscriber access only
Momotaro-Gene Inc. - financials
| Fiscal Year Ended | Mar 31, 2015 | Mar 31, 2016 | Mar 31, 2017 | Mar 31, 2018 | Mar 31, 2019 | Mar 31, 2020 | Mar 31, 2021 | Mar 31, 2022 | Mar 31, 2023 | Mar 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 95,344,000 | 59,310,000 | - | - | - | - | - | - | - | - |
| % Revenue Growth (YoY) | - | (37.8%) | - | - | - | - | - | - | - | - |
| EBITDA (USD) | (45,371,000) | (151,988,000) | - | (335,058,000) | (400,036,000) | - | (373,952,000) | - | - | - |
| Operating Income (USD) | (45,683,000) | (152,135,000) | - | (335,222,000) | (400,214,000) | - | (374,078,000) | - | - | - |
| Operating Margin | (47.9%) | (256.5%) | - | - | - | - | - | - | - | - |
| % EBITDA Margin | (47.6%) | (256.3%) | - | - | - | - | - | - | - | - |
| NET Income (USD) | (56,250,000) | (157,223,000) | - | (336,920,000) | (403,881,000) | - | (376,028,000) | - | - | - |
| % Net Margin | (59.0%) | (265.1%) | - | - | - | - | - | - | - | - |
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.